Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Affect measures

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    134 result(s) found for: Affect measures. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2014-001012-19 Sponsor Protocol Number: CFTY720DNL02T Start Date*: 2014-12-17
    Sponsor Name:VU University Medical Center
    Full Title: Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis
    Medical condition: Relapsing-remitting (RR) multiple sclerosis (MS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004920-40 Sponsor Protocol Number: AFFECT Start Date*: 2021-03-22
    Sponsor Name:Vestre Viken HF
    Full Title: Affective effects of pre-surgery opioids (AFFECT): a randomized double-blind controlled trial
    Medical condition: Healthy adult surgery patients. Health status ASA1 or ASA2 as categorised by a medical doctor at the hospital based on medical history, physical examination. The American Society of Anesthesiologis...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000853-37 Sponsor Protocol Number: SCH/07/006 Start Date*: 2009-01-20
    Sponsor Name:Sheffield Children's NHS Foundation Trust
    Full Title: Botulinum Toxin: an adjunct in limb reconstruction – can it reduce pain and joint complications in the lengthening phase?
    Medical condition: The surgery to correct leg & foot deformities in children is a lengthy, & sometimes, difficult procedure. Metal frames are attached to the leg and / or foot and over a period of time the frame is m...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002138-13 Sponsor Protocol Number: GWSP0702 Start Date*: 2007-09-13
    Sponsor Name:GW Pharma Ltd.
    Full Title: A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).
    Medical condition: Symptoms of spasticity in multiple sclerosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000041-40 Sponsor Protocol Number: P131 Start Date*: 2022-02-22
    Sponsor Name:Maastricht University
    Full Title: A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001385-16 Sponsor Protocol Number: BACTstudy Start Date*: 2019-11-22
    Sponsor Name:Clinic for Medicine and rehabilitation, Nord-Trondelag Trust (HNT)
    Full Title: Botulinum toxin A in frequent and chronic tension-type headache. A double blind, randomized, placebo-controlled cross-over trial
    Medical condition: Frequent and chronic tension-type headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004177-83 Sponsor Protocol Number: 37202 Start Date*: 2011-11-14
    Sponsor Name:Academic Medical Center
    Full Title: Boosting the oxytocin system in acute trauma: The effectiveness of intranasal oxytocin treatments and stimulation of social support on preventing trauma related psychopathology
    Medical condition: Posttraumatic Stress Disorder (PTSD) according to criteria in the DSM-IV
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10036316 Post-traumatic stress disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015800-25 Sponsor Protocol Number: 810 Start Date*: 2010-01-19
    Sponsor Name:The Liverpool Heart & Chest Hospital NHS Trust
    Full Title: A pilot randomised control trial, in intensive care patients, comparing seven days versus two days treatment with empirical antibiotics to treat hospital acquired infection of unknown origin
    Medical condition: Healthcare associated infections This includes infections of the: • Skin and underneath the skin, including muscle - sometimes called ‘soft tissue’ • Urinary tract - including your kidneys or bladd...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003655-20 Sponsor Protocol Number: GWPHN0602 Start Date*: 2008-11-21
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of post-herpetic neuralgia.
    Medical condition: Post-herpetic neuralgia symptom relief.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001217-25 Sponsor Protocol Number: 2016-001217-25 Start Date*: 2016-09-07
    Sponsor Name:Uppsala University
    Full Title: Emotion, Serotonin and Premenstrual Dysphoric Disorder (EmSeP)
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008342-20 Sponsor Protocol Number: RAA08-015 Start Date*: 2009-02-23
    Sponsor Name:King's College London
    Full Title: Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit).
    Medical condition: Down's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005772-13 Sponsor Protocol Number: AMISU_L_01008 Start Date*: 2008-01-28
    Sponsor Name:sanofi-aventis Zrt.
    Full Title: Comparative efficacy of amisulpride vs. risperidone on cognitive functions in patients with chronic schizophrenia.
    Medical condition: measure of overall cognitive functioning in chronic schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-003664-25 Sponsor Protocol Number: 11323 Start Date*: 2023-12-21
    Sponsor Name:University Medical Center Groningen
    Full Title: The impact of gender differences in P-glycoprotein function measured with [18F]MC225 and PET
    Medical condition: Gender, healthy volunteers
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019897-33 Sponsor Protocol Number: 2522518514 Start Date*: 2011-04-14
    Sponsor Name:erasmus mc
    Full Title: Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia
    Medical condition: patients with psychotic symptoms, diagnosed with schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003652-11 Sponsor Protocol Number: NAI007 Start Date*: 2008-09-01
    Sponsor Name:University of Dundee
    Full Title: A proof of concept study to evaluate the peak bronchoprotection conferred by single and chronic dosing with levosalbutamol and racemic salbutamol in persistent asthmatics.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005265-11 Sponsor Protocol Number: GWMS0501 Start Date*: 2006-04-03
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sc...
    Medical condition: Relief of central neuropathic pain in subjects with multiple sclerosis (MS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020002-15 Sponsor Protocol Number: A3921061 Start Date*: 2010-11-15
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Medical condition: Moderate To Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Completed) NL (Completed) FI (Prematurely Ended) ES (Completed) DK (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) AT (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000342-19 Sponsor Protocol Number: ML28702 Start Date*: 2013-10-24
    Sponsor Name:Roche Nederland B.V.
    Full Title: MULTI-CENTER, OPEN LABEL, SINGLE ARM PHASE IIIB STUDY ON SAFETY AND EFFICACY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) IN MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGIC DI...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020003-73 Sponsor Protocol Number: A3921079 Start Date*: 2011-03-31
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 USA
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-019988-10 Sponsor Protocol Number: A3921078 Start Date*: 2011-04-05
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE...
    Medical condition: CHRONIC PLAQUE PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 14:00:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA